DongKoo Bio & Pharma Overview
- Year Founded
-
1970
- Status
-
Public
- Employees
-
446
- Stock Symbol
-
006620
- Investments
-
8
- Share Price
-
$2.54
- (As of Friday Closing)
DongKoo Bio & Pharma General Information
Description
Dongkoo Bio&Pharma Co Ltd is engaged in the research, development, manufacture, and sale of pharmaceuticals products. The company provides products for digestants, other analgesics and antipyretics, nonsteroidal anti-inflammatory drugs, oral hypoglycemic agents, antiplatelet agents, antihistamines and anti-allergic, and decongestants and nasal sprays. It offers its products in multiple forms such as capsules, tablet, powder, granule, and liquid. The company exports its products to various countries including Vietnam, New Zealand, Thailand, Hong Kong and Singapore.
Contact Information
Website
www.dongkoo.comCorporate Office
- 14th Floor, Building B
- 114 Beobwon-ro, Songpa-gu
- Seoul, Guro-gu 05854
- South Korea
Corporate Office
- 14th Floor, Building B
- 114 Beobwon-ro, Songpa-gu
- Seoul, Guro-gu 05854
- South Korea
DongKoo Bio & Pharma Stock Performance
As of 13-Nov-2026, DongKoo Bio & Pharma’s stock price is $2.54. Its current market cap is $66.5M with 26.2M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.54 | $2.54 | $2.26 - $4.29 | $66.5M | 26.2M | 82.7K | $0.84 |
DongKoo Bio & Pharma Financials Summary
As of 30-Jun-2026, DongKoo Bio & Pharma has a trailing 12-month revenue of $166M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 122,327 | 161,653 | 116,405 | 132,666 |
| Revenue | 166,362 | 170,530 | 182,694 | 164,967 |
| EBITDA | 37,771 | 51,761 | 10,086 | 16,994 |
| Net Income | 22,748 | 35,325 | 1,492 | 9,034 |
| Total Assets | 206,478 | 233,575 | 165,693 | 148,294 |
| Total Debt | 79,474 | 89,431 | 58,821 | 33,991 |
DongKoo Bio & Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
DongKoo Bio & Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
DongKoo Bio & Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
DongKoo Bio & Pharma Patents
DongKoo Bio & Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2019013403-A1 | Agents for preventing or treating urinary disease and preparing the same | Inactive | 11-Jul-2017 | ||
| WO-2018080284-A1 | Pharmaceutical composition for enhancing bioavailability of drug for treatment of acne | Inactive | 31-Oct-2016 | ||
| ES-2848728-T3 | Injection medical device | Active | 25-May-2016 | ||
| JP-2019517897-A | Medical infusion system | Active | 25-May-2016 | ||
| JP-6529104-B1 | Medical infusion system | Active | 25-May-2016 | A61M5/168 |
DongKoo Bio & Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
DongKoo Bio & Pharma Investments & Acquisitions (8)
DongKoo Bio & Pharma’s most recent deal was a PIPE with Qurient for . The deal was made on 09-May-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Qurient | 09-May-2025 | PIPE | Drug Discovery | ||
| Arummedics | 17-Mar-2025 | Corporate | Specialty Chemicals | ||
| Picoentech | 05-Aug-2024 | Later Stage VC | Biotechnology | ||
| Qurient | 12-Apr-2024 | PIPE | Drug Discovery | ||
| Ampoule Manufacturing Plant (Munkin Tun / DongKoo / MEIC) | 01-Jan-2024 | Joint Venture | Pharmaceuticals |
DongKoo Bio & Pharma ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
DongKoo Bio & Pharma Exits (1)
DongKoo Bio & Pharma’s most recent exit was on 06-Jul-2023 from Verismo Therapeutics. The exit was categorized as with 5 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Verismo Therapeutics | 06-Jul-2023 | Completed |
|
DongKoo Bio & Pharma FAQs
-
When was DongKoo Bio & Pharma founded?
DongKoo Bio & Pharma was founded in 1970.
-
Where is DongKoo Bio & Pharma headquartered?
DongKoo Bio & Pharma is headquartered in Seoul, South Korea.
-
What is the size of DongKoo Bio & Pharma?
DongKoo Bio & Pharma has 446 total employees.
-
What industry is DongKoo Bio & Pharma in?
DongKoo Bio & Pharma’s primary industry is Drug Discovery.
-
Is DongKoo Bio & Pharma a private or public company?
DongKoo Bio & Pharma is a Public company.
-
What is DongKoo Bio & Pharma’s stock symbol?
The ticker symbol for DongKoo Bio & Pharma is 006620.
-
What is the current stock price of DongKoo Bio & Pharma?
As of 13-Nov-2026 the stock price of DongKoo Bio & Pharma is $2.54.
-
What is the current market cap of DongKoo Bio & Pharma?
The current market capitalization of DongKoo Bio & Pharma is $66.5M.
-
What is DongKoo Bio & Pharma’s current revenue?
The trailing twelve month revenue for DongKoo Bio & Pharma is $166M.
-
What is DongKoo Bio & Pharma’s annual earnings per share (EPS)?
DongKoo Bio & Pharma’s EPS for 12 months was $0.84.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
